Sorry, you need to enable JavaScript to visit this website.

Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis

Safety Study of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor in Subjects With Rheumatoid Arthritis [Phase 3b/4 Randomized Safety Endpoint Study of 2 Doses of Tofacitinib in Comparison to A Tumor Necrosis Factor (TNF) Inhibitor in Subjects with Rheumatoid Arthritis

Category & Conditions: Immune System Diseases and Conditions
Medicine: XELJANZ®(TOFACITINIB)
ClinicalTrials.gov Identifier (NCT): NCT02092467
Protocol ID: A3921133
    Share
PrintDownload
Open Plain Language Summary Result: Click here